Onconova Therapeutics, Inc. (NASDAQ:ONTX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On November 23, 2020, Onconova Therapeutics, Inc. (“Onconova” or the “Company”) issued a press release announcing that it has submitted an Investigational New Drug application for its product candidate ON 123300 to the U.S. Food and Drug Administration (“FDA”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information disclosed under this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On November 20, 2020, Onconova submitted an Investigational New Drug application for its product candidate ON 123300 to the FDA. Following FDA review and Institutional Review Board approval, the Company plans to begin a Phase 1 study of ON 123300 in the United States.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press release of Onconova Therapeutics, Inc. issued on November 23, 2020|
Onconova Therapeutics, Inc. Exhibit
EX-99.1 2 tm2035871d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 ·U.S. Phase 1 trial patient enrollment to begin in the first half of 2021 ·China Phase 1 trial enrollment ongoing ·Key regulatory milestone achieved to enable further study of product candidate for patients with HR+ HER 2- metastatic breast cancer and other tumors NEWTOWN,…
To view the full exhibit click
About Onconova Therapeutics, Inc. (NASDAQ:ONTX)
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.